Aclaris Therapeutics reports Q3 2026 loss, $204.6 M cash and Phase 1b data for ATI‑052
Aclaris Therapeutics announced third‑quarter 2026 revenue of $1.5 million and a net loss of $18.5 million, or $0.12 per share. The company ended the quarter with $204.6 million in cash, cash equivalents and marketable securities, extending its operating runway to the first half of 2029. Positive Phase 1b proof‑of‑concept results were reported for ATI‑052 in atopic dermatitis and asthma.
Why it matters
The company said the cash balance and recent offering proceeds will fund operations through mid‑2029, giving investors a longer liquidity horizon. The Phase 1b data could de‑risk future development of ATI‑052, potentially enhancing the company’s valuation.
Key facts
- 1Q3 2026 revenue was $1.5 million. tradingview.com
- 2Q3 2026 net loss was $18.5 million. tradingview.com
- 3Loss per basic and diluted share was $0.12. tradingview.com
- 4Cash, cash equivalents and marketable securities totaled $204.6 million at September 30. tradingview.com
- 5Resources are expected to fund operations through the first half of 2029. tradingview.com
- 6Positive Phase 1b results were reported for ATI‑052 in atopic dermatitis and asthma. tradingview.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.